Arrivent Biopharma, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
ArriVent BioPharma, a clinical-stage biopharmaceutical company, reported significant operating losses for fiscal year 2025 while advancing its lead oncology candidates, firmonertinib and ARR-217, through pivotal clinical trials and strategic collaborations.
NASDAQ
ArriVent BioPharma details its 2024 financial performance and provides updates on the clinical development of firmonertinib and its ADC collaborations.
NASDAQ
ArriVent BioPharma's 10-K filing outlines the company's registered securities, financial status, and ongoing clinical trials, particularly for their lead drug candidate, furmonertinib.